Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer

被引:31
作者
Nakopoulou, L
Katsarou, S
Giannopoulou, I
Alexandrou, P
Tsirmpa, I
Panayotopoulou, E
Mavrommatis, J
Keramopoulos, A
机构
[1] Natl & Kapodistrian Univ Athens, Sch Med, Dept Pathol, GR-11527 Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Sch Med, Dept Gynaecol & Obstet 1, GR-11527 Athens, Greece
关键词
breast cancer; immunohistochemistry; survival; TIMP-2; tumor growth;
D O I
10.1038/modpathol.3880486
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Tissue inhibitors of metalloproteinases (TIMPs) are endogenous regulators of matrix metalloproteinases (MMPs). They are believed to possess several distinct cellular functions, particularly the contradictory activities of inhibiting MMPs and promoting tumor cell growth. Immunohistochemistry was performed to detect TIMP-2 protein in 136 infiltrative breast carcinomas. TIMP-2 protein was analyzed in parallel with clinicopathologic features (tumor size, histologic type, nuclear and histologic grade, stage), patients' overall survival and ER, PR, Ki-67, topo IIalpha, c-erbB-2, p53 and bcl-2 proteins. Statistical analysis was performed using univariate and multivariate models analysis. Immunoreactivity for TIMP-2 was observed in cancer cells and stromal. fibroblasts in 106 (77.94%) and 104 (76.47%) of 136 cases, respectively. TIMP-2 protein expression in stromal fibroblasts showed a statistically significant inverse correlation with tumor size (P = .014). An inverse correlation was also observed between TIMP-2 epithelial immunoreactivity and nuclear and histologic grade (P = .036 and P = .007, respectively). TIMP-2 protein reactivity showed statistically significant positive associations with topo IIalpha and bcl-2 in stromal and cancer cells, respectively (P = .032 and P = .001, respectively). TIMP-2 protein expression in cancer and stromal cells was associated with better patients' overall survival (P = .002 and P = .038, respectively). When evaluated by the Cox's proportional hazard regression model, this association was further established, but only as far as TIMP-2 expression in tumor epithelium was concerned (P = .019). Our results support the multifunctional potential of TIMP-2 through its correlation on the one hand to a favorable outcome, due to its MMP inhibitory activity and on the other to topo IIalpha contributing to its growth factor activity.
引用
收藏
页码:26 / 34
页数:9
相关论文
共 50 条
  • [31] Matrix metalloproteinase-2,-9,-12, and tissue inhibitor of metalloproteinase 2 gene polymorphisms and cutaneous expressions in patients with Behcet's disease
    Park, K. S.
    Min, Y.
    Park, S. R.
    Kim, E. H.
    Lee, D. J.
    Bang, D.
    Lee, E. -S.
    TISSUE ANTIGENS, 2012, 79 (05): : 333 - 339
  • [32] Is tissue inhibitor of metalloproteinase-1 a new prognosticator for breast cancer? An analysis of 266 cases
    Neri, Alessandro
    Megha, Tiziana
    Bettarini, Francesca
    Tacchini, Damiana
    Mastrogiulio, Maria Grazia
    Marrelli, Daniele
    Pinto, Enrico
    Tosi, Piero
    HUMAN PATHOLOGY, 2012, 43 (08) : 1184 - 1191
  • [33] Thioredoxin secreted upon ultraviolet A irradiation modulates activities of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in human dermal fibroblasts
    Oh, JH
    Chung, AS
    Steinbrenner, H
    Sies, H
    Brenneisen, P
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2004, 423 (01) : 218 - 226
  • [34] Matrix metalloproteinase-2,-9, and tissue inhibitor of MMP-2 gene polymorphisms in Taiwanese periodontitis patients
    Hsiao, Yu-Feng
    Yang, Li-Chiu
    Chou, Yu-Shian
    Ho, Ya-Ping
    Lin, Ying-Chu
    Ho, Kun-Yen
    Wu, Yi-Min
    Tsai, Chi-Cheng
    JOURNAL OF DENTAL SCIENCES, 2016, 11 (04) : 411 - 418
  • [35] Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma
    Yoshizaki, T
    Maruyama, Y
    Sato, H
    Furukawa, M
    INTERNATIONAL JOURNAL OF CANCER, 2001, 95 (01) : 44 - 50
  • [36] High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis
    Kim, Tae-Joong
    Rho, Seung Bae
    Choi, Yoon-La
    Choi, Chet Hun
    Lee, Jeong-Won
    Bae, Duk-Soo
    Ahn, Geunghwan
    Lee, Je-Ho
    Kim, Byoung-Gie
    HUMAN PATHOLOGY, 2006, 37 (07) : 906 - 913
  • [37] Cancer-Specific Survival Stratification Derived from Tumor Expression of Tissue Inhibitor of Metalloproteinase-2 in Non-Metastatic Renal Cell Carcinoma
    Beardo, Pastora
    Truan Cacho, David
    Izquierdo, Laura
    Bautista Alcover-Garcia, Joan
    Alcaraz, Antonio
    Extramiana, Javier
    Mallofre, Carmen
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (01) : 289 - 299
  • [38] Impacts of Matrix Metalloproteinase-2 Promoter Genotypes on Breast Cancer Risk
    Hung, Chih-Chiang
    Tsai, Chung-Lin
    Chin, Yu-Ting
    Wang, Yun-Chi
    Liu, Chia-Hua
    Lin, Meng-Liang
    Chen, Shih-Shun
    He, Jie-Long
    Tsai, Chia-Wen
    Su, Chen-Hsien
    Bau, Da-Tian
    Chang, Wen-Shin
    CANCER GENOMICS & PROTEOMICS, 2024, 21 (05) : 502 - 510
  • [39] The effects of N-acetylcysteine on the expression of matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in hepatic fibrosis in bile duct ligated rats
    Rezaei, Arezou
    Ardestani, Sussan Kaboudanian
    Forouzandeh, Mehdi
    Tavangar, Seyed Mohammad
    Khorramizadeh, Mohammad Reza
    Payabvash, Seyedmehdi
    Nezami, Behtash Ghazi
    Jahanshiri, Zahra
    Tavakoli, Zahra
    Shariftabrizi, Ahmad
    Dehpour, Ahmad Reza
    HEPATOLOGY RESEARCH, 2008, 38 (12) : 1252 - 1263
  • [40] Cutting to the Chase: How Matrix Metalloproteinase-2 Activity Controls Breast-Cancer-to-Bone Metastasis
    Tauro, Marilena
    Lynch, Conor C.
    CANCERS, 2018, 10 (06)